138 related articles for article (PubMed ID: 6897633)
1. Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone.
Ideström K; Kimby E; Björkholm M; Mellstedt H; Engstedt L; Gahrton G; Johansson B; Killander D; Robérts KH; Stalfelt AM; Udén AM; Wadman B; Wählby S
Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1117-23. PubMed ID: 6897633
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents.
Pedersen-Bjergaard J; Hansen MM; Geisler CH; Nissen NI
Acta Med Scand; 1980; 207(3):215-20. PubMed ID: 6989170
[TBL] [Abstract][Full Text] [Related]
3. A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer.
Løber J; Mouridsen HT; Christiansen IE; Dombernowsky P; Mattsson W; Rørth M
Cancer; 1983 Nov; 52(9):1570-6. PubMed ID: 6352005
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration.
Loos U; Musch E; Malek M; Riedel E
Oncology; 1991; 48(4):334-42. PubMed ID: 1891177
[TBL] [Abstract][Full Text] [Related]
5. [Phase II study of prednimustine in follicular lymphoma and chronic lymphocytic leukemia].
Ito Y; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ueno K; Imajou K; Miyaoka K; Ozeki H
Gan To Kagaku Ryoho; 1987 Jan; 14(1):173-8. PubMed ID: 3541792
[TBL] [Abstract][Full Text] [Related]
6. Treatment of refractory chronic lymphocytic leukemia with prednimustine: a phase II study using strict response criteria.
Gandara DR; George CB; Ries CA; Koretz MM; Lewis JP
Cancer Chemother Pharmacol; 1987; 19(2):165-8. PubMed ID: 3568275
[TBL] [Abstract][Full Text] [Related]
7. A phase II clinical trial of prednimustine. Clinical screening cooperative group of E.O.R.T.C.
Biomedicine; 1977 Jun; 27(4):158-61. PubMed ID: 329910
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts.
Gandara DR; Ries CA; Schiff SA; George CB; Lewis JP; Koretz MM; Carter SK
Cancer Chemother Pharmacol; 1982; 9(1):10-2. PubMed ID: 7139848
[TBL] [Abstract][Full Text] [Related]
9. [Effect of Prednimustine (Leo 1031) in chronic lymphatic leukemia].
Lutz D; Böhnel J
Osterr Z Onkol; 1977; 3(5-6):155-9. PubMed ID: 323777
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of Prednimustine. Leo-1031 (NSC-134087) in acute non-lymphocytic leukemia.
Juul K; Sørensen P; Pedersen-Bjergaard J; Jensen MK
Scand J Haematol; 1979 Nov; 23(5):388-92. PubMed ID: 396664
[TBL] [Abstract][Full Text] [Related]
11. Prednimustine in refractory non-Hodgkin's lymphoma: a phase II study of the Northern California Oncology Group.
Gandara DR; Wold HG; Redmond J; Kohler M; Reynolds R; Wong P; Forsythe J; Fisher K; Lewis B
Semin Oncol; 1986 Mar; 13(1 Suppl 1):14-8. PubMed ID: 3952517
[TBL] [Abstract][Full Text] [Related]
12. Prednisolone plasma levels after oral administration of Prednimustine. Comparison with levels obtained after administration of an equimolar dose of prednisolone.
Sayed A; Hove WV; Vermeulen A
Oncology; 1981; 38(6):351-5. PubMed ID: 7301281
[TBL] [Abstract][Full Text] [Related]
13. Continuous versus intermittent prednimustine treatment of non-Hodgkin's lymphoma.
Hatschek T; Baldetorp L; Carstensen J; Håkansson L; Möller T; Nilsson B; Termander B
Med Oncol Tumor Pharmacother; 1993; 10(4):159-66. PubMed ID: 8164452
[TBL] [Abstract][Full Text] [Related]
14. Prednimustine (NSC-134087, Leo 1031) treatment of lymphocytic and lymphocytic-histiocytic lymphomas.
Mattsson W; von Eyben F; Turesson I; Wählby S
Cancer; 1978 Jan; 41(1):112-6. PubMed ID: 342081
[TBL] [Abstract][Full Text] [Related]
15. Studies on the pharmacokinetics of chlorambucil and prednimustine in man.
Newell DR; Calvert AH; Harrap KR; McElwain TJ
Br J Clin Pharmacol; 1983 Feb; 15(2):253-8. PubMed ID: 6849759
[TBL] [Abstract][Full Text] [Related]
16. Prednimustine treatment in malignant lymphomas.
Szántó I; Fleischmann T; Eckhardt S
Oncology; 1989; 46(4):205-7. PubMed ID: 2662086
[TBL] [Abstract][Full Text] [Related]
17. Comparative carcinogenic activity of prednimustine, chlorambucil, prednisolone and chlorambucil plus prednisolone in Sprague-Dawley rats.
Berger MR; Habs M; Schmähl D
Arch Geschwulstforsch; 1985; 55(6):429-42. PubMed ID: 4083998
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients.
Bastholt L; Johansson CJ; Pfeiffer P; Svensson L; Johansson SA; Gunnarsson PO; Mouridsen H
Cancer Chemother Pharmacol; 1991; 28(3):205-10. PubMed ID: 1855277
[TBL] [Abstract][Full Text] [Related]
19. Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A 9-year experience at a single institution.
Roncadin M; Arcicasa M; Zagonel V; Bortolus R; Valeri P; Pinto A; De Paoli A; Franchin G; Carbone A; Trovò MG
Cancer; 1994 Aug; 74(3):978-84. PubMed ID: 8039128
[TBL] [Abstract][Full Text] [Related]
20. The antitumor effect of prednimustine in vitro and in vivo.
Hartley-Asp B
Semin Oncol; 1986 Mar; 13(1 Suppl 1):3-7. PubMed ID: 3952519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
